Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy

BACKGROUND: In the phase III MONARCH 2 study (NCT02107703), abemaciclib plus fulvestrant significantly improved progression‐free survival (PFS) versus placebo plus fulvestrant in patients with hormone receptor‐positive (HR+), HER2‐negative advanced breast cancer (ABC). This study assessed patient‐re...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaufman, Peter A., Toi, Masakazu, Neven, Patrick, Sohn, Joohyuk, Grischke, Eva‐Maria, Andre, Valerie, Stoffregen, Clemens, Shekarriz, Sarah, Price, Gregory L., Carter, Gebra Cuyun, Sledge, George W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2019
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011625/
https://www.ncbi.nlm.nih.gov/pubmed/32043763
http://dx.doi.org/10.1634/theoncologist.2019-0551

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7011625/
https://www.ncbi.nlm.nih.gov/pubmed/32043763
http://dx.doi.org/10.1634/theoncologist.2019-0551

Ejemplares similares